| Secukinumab in plaque psoriasis—results of two phase 3 trials RG Langley, BE Elewski, M Lebwohl, K Reich, CEM Griffiths, K Papp, ... New England Journal of Medicine 371 (4), 326-338, 2014 | 2115 | 2014 |
| Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial IB McInnes, A Kavanaugh, AB Gottlieb, L Puig, P Rahman, C Ritchlin, ... The Lancet 382 (9894), 780-789, 2013 | 874 | 2013 |
| Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions BB Davidovici, N Sattar, PC Jörg, L Puig, P Emery, JN Barker, ... Journal of Investigative Dermatology 130 (7), 1785-1796, 2010 | 827 | 2010 |
| Phase 3 studies comparing brodalumab with ustekinumab in psoriasis M Lebwohl, B Strober, A Menter, K Gordon, J Weglowska, L Puig, K Papp, ... New England Journal of Medicine 373 (14), 1318-1328, 2015 | 783 | 2015 |
| Epidemiology of atopic dermatitis in adults: results from an international survey S Barbarot, S Auziere, A Gadkari, G Girolomoni, L Puig, EL Simpson, ... Allergy 73 (6), 1284-1293, 2018 | 691 | 2018 |
| Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological … C Ritchlin, P Rahman, A Kavanaugh, IB McInnes, L Puig, S Li, Y Wang, ... Annals of the rheumatic diseases 73 (6), 990-999, 2014 | 690 | 2014 |
| Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and … KB Gordon, B Strober, M Lebwohl, M Augustin, A Blauvelt, Y Poulin, ... The Lancet 392 (10148), 650-661, 2018 | 541 | 2018 |
| Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey MG Lebwohl, H Bachelez, J Barker, G Girolomoni, A Kavanaugh, ... Journal of the American Academy of Dermatology 70 (5), 871-881. e30, 2014 | 540 | 2014 |
| European consensus statement on phenotypes of pustular psoriasis AA Navarini, AD Burden, F Capon, U Mrowietz, L Puig, S Köks, K Kingo, ... Journal of the European Academy of Dermatology and Venereology 31 (11), 1792 …, 2017 | 343 | 2017 |
| Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double‐blind, phase III NAVIGATE trial RG Langley, TF Tsai, S Flavin, M Song, B Randazzo, Y Wasfi, J Jiang, ... British Journal of Dermatology 178 (1), 114-123, 2018 | 329 | 2018 |
| Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of … A Kavanaugh, C Ritchlin, P Rahman, L Puig, AB Gottlieb, S Li, Y Wang, ... Annals of the rheumatic diseases 73 (6), 1000-1006, 2014 | 305 | 2014 |
| Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity CC Zouboulis, T Tzellos, A Kyrgidis, GBE Jemec, FG Bechara, ... British journal of dermatology 177 (5), 1401-1409, 2017 | 293 | 2017 |
| The role of IL‐23 and the IL‐23/TH17 immune axis in the pathogenesis and treatment of psoriasis G Girolomoni, R Strohal, L Puig, H Bachelez, J Barker, WH Boehncke, ... Journal of the European Academy of Dermatology and Venereology 31 (10), 1616 …, 2017 | 234 | 2017 |
| Actinic keratosis with atypical basal cells (AK I) is the most common lesion associated with invasive squamous cell carcinoma of the skin MT Fernandez‐Figueras, C Carrato, X Sáenz, L Puig, E Musulen, ... Journal of the European Academy of Dermatology and Venereology 29 (5), 991-997, 2015 | 231 | 2015 |
| Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin‐17 inhibitors and their practical management DM Saunte, U Mrowietz, L Puig, C Zachariae British Journal of Dermatology 177 (1), 47-62, 2017 | 220 | 2017 |
| Obesity and psoriasis: body weight and body mass index influence the response to biological treatment L Puig Journal of the European Academy of Dermatology and Venereology 25 (9), 1007-1011, 2011 | 211 | 2011 |
| Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies JMGR de Morales, L Puig, E Daudén, JD Cañete, JL Pablos, AO Martín, ... Autoimmunity reviews 19 (1), 102429, 2020 | 201 | 2020 |
| PASI 90 response: the new standard in therapeutic efficacy for psoriasis L Puig Journal of the European Academy of Dermatology and Venereology 29 (4), 645-648, 2015 | 198 | 2015 |
| A consensus report on appropriate treatment optimization and transitioning in the management of moderate‐to‐severe plaque psoriasis U Mrowietz, E De Jong, K Kragballe, R Langley, A Nast, L Puig, K Reich, ... Journal of the European Academy of Dermatology and Venereology 28 (4), 438-453, 2014 | 189 | 2014 |
| Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis AW Armstrong, L Puig, A Joshi, M Skup, D Williams, J Li, KA Betts, ... JAMA dermatology 156 (3), 258-269, 2020 | 185 | 2020 |
MT Fernández-FiguerasAssociate Professor Universitat Internacional de Catalunya在 quironsalud.es 的电子邮件经过验证
